CRISPR Targets PCSK9 for Cholesterol Reduction

P

Peter Attia MD podcast episode with Feng Zhang

General HealthContent

Quotes From Source

“Liver is quite robust, achieving 80-90% efficacy...”

Story of claim

Feng Zhang explains CRISPR's potential to target the PCSK9 gene using lipid nanoparticles to treat genetic liver diseases and manage cholesterol levels.

  • Goal: To treat genetic liver diseases and reduce cholesterol levels using CRISPR.
  • Proof: Liver's lipid recycling aids in efficient CRISPR delivery, offering high potential efficacy in liver-targeted therapies.
  • Nuances:
    • Liver's lipid recycling aids in nanoparticle delivery
    • Paralyzing PCSK9 could reduce cholesterol levels
  • Impact on Life: Could lead to effective management of liver diseases and cardiovascular risks.

Investments

  • Price: Potentially high due to development and clinical testing
  • Time: Ongoing research with promising early results
  • Effort: Significant due to complexity of delivery systems

Risks

Possible off-target effects and delivery challenges.

Get Started 🚀

  • Develop lipid nanoparticle delivery systems
  • Target PCSK9 gene to lower cholesterol
  • Monitor treatment efficacy and safety

Brogevity AI can make mistakes. Check important info.

Reference Video